In the News

Learn about the 19 students who completed the 2019 Summer Undergraduate Research Program (SURP) at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK).

Discover some of the latest innovations in chemotherapy for breast cancer.

Find out how to handle feelings of self-blame and shame that may accompany a cancer diagnosis.

MSK studies look at the role of RNA splicing factors in acute myeloid leukemia and melanoma.

Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.

Scientists at Memorial Sloan Kettering have created a model of rectal cancer using human-tumor-derived organoids.

A class of drugs originally developed to treat certain neurological disorders appears to boost the production of red blood cells.

MSK Kids is leading a major effort to fully deliver on the promise of precision medicine for our youngest patients.

Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to cobimetinib in treatment of patients with histiocytic neoplasms (HN) (Erdheim-Chester Disease, Rosai-Dorfman, Langerhans Histiocytosis), who do not harbor the BRAF V600 mutation. Cobimetinib is an oral inhibitor of MEK1 and MEK2 currently approved to treat melanoma. This designation was granted based on data submitted by MSK, in collaboration with Genentech, a member of the Roche Group, from a phase II trial of single-agent cobimetinib for adults with histiocytic disorders (published in Nature in March 2019 by Eli Diamond, MD; Omar Abdel-Wahab, MD; and David Hyman, MD).

Learn about MSK's new Program for Drug Development in Leukemia (PDD-L), which will offer more clinical trials for many types of leukemia.